# SARS-CoV-2 Vaccine Pregnancy Registry

> **NIH NIH U24** · GEORGE WASHINGTON UNIVERSITY · 2023 · $250,000

## Abstract

PROJECT SUMMARY
SARS-CoV-2 was first detected in December 2019 and rapidly spread to become a pandemic.
Pregnant people are one of the groups at high-risk for morbidity and mortality. It is safe to
assume that pregnant people will continue to be exposed to SARS-CoV-2 vaccination. SARS-
CoV-2 vaccination continues to date, and boosters are likely to be recommended on an annual
basis.
There is limited information regarding the potential long-term benefit from fetal exposure to
SARS-CoV-2 vaccine, and most of the data are from self-reported surveys or administrative
databases. One of concern about exposures to infections in pregnancy focuses on
neurodevelopmental outcomes of the offspring.
We propose a multi-center prospective observational study of the offspring of 500 individuals
that did and did not receive a SARS-CoV-2 vaccine during pregnancy. The proposed study will
leverage the MFMU Network’s large and robust research infrastructure to evaluate if SARS-
CoV-2 vaccines are associated with improved neurodevelopmental outcomes in the offspring,
which has been a neglected area of investigation with regard to COVID-19.
The aims of this project are,
Aim 1: To identify a cohort of individuals who received the SARS-CoV-2 vaccine during
pregnancy or within 30 days prior to pregnancy and compare the developmental outcomes of
their infants at age 24 months with those who did not receive the vaccine during pregnancy or
within 30 days prior to pregnancy.
Aim 2: Compare specific developmental outcomes of the offspring at age 24 months of those
who received SARS-CoV-2 vaccine during pregnancy or within 30 days prior to pregnancy with
those who did not
Aim 3: Compare behavioral outcomes of the offspring at age 24 months of those who received
SARS-CoV-2 vaccine during pregnancy or within 30 days prior to pregnancy with those who did
not.
Aim 4: Compare autism screening test outcomes of the offspring at age 24 months of those who
received SARS-CoV-2 vaccine during pregnancy or within 30 days prior to pregnancy with those
who did not.

## Key facts

- **NIH application ID:** 10879795
- **Project number:** 3U24HD036801-26S1
- **Recipient organization:** GEORGE WASHINGTON UNIVERSITY
- **Principal Investigator:** Rebecca Gersnoviez Clifton
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $250,000
- **Award type:** 3
- **Project period:** 1998-04-15 → 2030-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10879795

## Citation

> US National Institutes of Health, RePORTER application 10879795, SARS-CoV-2 Vaccine Pregnancy Registry (3U24HD036801-26S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10879795. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*